Just when you thought the cycling world couldn’t throw another curveball, Christophe Laporte’s withdrawal from the Samyn Classic has left fans and his team, Visma-Lease a Bike, reeling. While the team celebrated Wout van Aert’s return from illness, Laporte’s absence feels like a gut punch. The Frenchman, who was expected to be a key player in the 203.8km cobbled Classic, was pulled from the race after his team reported he wasn’t feeling fully fit following Opening Weekend. But here’s where it gets even more frustrating: Laporte had been on a roll, kicking off his season with a stage win at the Vuelta a Andalucía and delivering strong performances during Opening Weekend. His absence isn’t just a loss for the team—it’s a blow to his own comeback story after a disastrous 2025 season, where a relentless bout of cytomegalovirus sidelined him from major races like the Classics and the Tour de France. And this is the part most people miss: cytomegalovirus isn’t just a minor illness—it’s a stubborn virus that can sap energy and linger, making a full recovery a slow and uncertain process. Laporte’s recent setback raises a controversial question: Is this just a minor hiccup, or is his fitness becoming a wildcard for the Spring Classics? His team, already grappling with a string of bad luck, must now navigate this uncertainty. Laporte himself seemed optimistic after Omloop Het Nieuwsblad, stating, ‘After an unlucky season last year, it’s nice to show myself again in races like this.’ But with this latest development, fans are left wondering: Can he truly reclaim his spot among the world’s top Classics riders? Or will 2026 be another year of what-ifs? Let’s spark a debate: Do you think Laporte’s setbacks are a temporary stumble, or is there a deeper issue at play? Share your thoughts in the comments—this is one conversation you won’t want to miss!
